These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1899 related articles for article (PubMed ID: 27065456)

  • 1. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS; Eskander RN; Monk BJ
    Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
    Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
    Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
    Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
    Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    Gourley C; Miller RE; Hollis RL; Ledermann JA
    Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Moschetta M; George A; Kaye SB; Banerjee S
    Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
    J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 95.